oxygen (15-o) water
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Mar 3, 2017 (NCT04600115)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 15-oxygen
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05134012 | Phase 3 | Apr 20, 2022 | MedTrace Pharma A/S |
| NCT04556552 | Phase 3 | Nov 13, 2020 | City University of New York, Emory University, Georgia Institute of Technology, National Institute on Drug Abuse (NIDA) |
| NCT04600115 | Early Phase 1 (Phase 1) | Mar 3, 2017 | National Heart, Lung, and Blood Institute (NHLBI), University of Utah |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| City University of New York | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Georgia Institute of Technology | Academic/Hospital | 1 | 0 | 1 | 2020 |
| MedTrace Pharma A/S | For profit | 1 | 1 | 1 | 2022 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2017 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2020 |
| University of Utah | Academic/Hospital | 1 | 1 | 1 | 2017 |
7 organizations
Page 1 / 1